WXXWY (WuXi Biologics (Cayman)) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WXXWY WuXi Biologics (Cayman) Inc WXXWY
100 GF Score
Price $9.47
GF Value $9.75
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) FFO?

FFO (Funds from operations) only applies to REITs.

WXXWY
100GF Score
WuXi Biologics (Cayman) Inc WXXWY
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is WuXi Biologics (Cayman) (WXXWY) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued. The current stock price of $9.47 is trading 2.8% below its estimated GF Value™ of $9.75. GuruFocus considers WuXi Biologics (Cayman) to be Fairly Valued.

Key valuation signals for WXXWY:

  • FFO:
  • GF Value™: $9.75 vs. price of $9.47 (2.8% below fair value)
  • GF Score™: 100/100 with 3 warning signs

No single metric tells the full story. See the WXXWY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
100GF Score

Get the complete analysis for WXXWY

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.47
Price
$9.75
GF Value